2025 brought no shortage of new ideas in Washington to reshape how the United States pays for medicines. From Most Favored Nation  (MFN) proposals to executive actions and broader drug pricing reforms, the policy debate moved quickly, with major implications for patients, investors, and the future of biomedical innovation.  Throughout the year, Incubate stayed at the cutting edge of that dialogue, bringing a consistent focus to what matters most: protecting access today while

This week, Incubate brought its voice to Capitol Hill, convening a fly-in with Patrick Jordan of NovaQuest Capital Management and Guarav Gupta of J.P. Morgan Chase & Co. to meet with key policymakers to discuss how federal policy can better support  early-stage biopharmaceutical innovation and the venture capital ecosystem that drives it. Incubate held strategic meetings with Senators John Cornyn (R-TX), Todd Young (R-IN), and Jon Husted (R-OH), as well as the Center for Medi

On the latest episode  of the Making Medicine podcast, Incubate executive director John Stanford sat down with Thomas Kaiser of Avicenna...

WASHINGTON ( April 16) -- Yesterday, President Trump issued an executive order  calling on Secretary of Health and Human Services Robert...

On March 26, Incubate executive director John Stanford joined a roundtable discussion hosted by The Hill  and the Alliance for Aging...

Incubate executive director John Stanford was recently featured in a PharmaVoice  article by reporter Amy Baxter on proposed reforms to...

BioWorld  regulatory editor Mari Serebrov recently interviewed Incubate's executive director John Stanford for her article on how the...

Incubate executive director John Stanford was recently featured in an Endpoints News  article by senior editor Zachary Brennan on...

WASHINGTON, D.C. (March 5, 2025) -- This week, Senators Thom Tillis (R-NC), Ted Budd (R-NC), Marsha Blackburn (R-TN), James Lankford...

We recently tallied six new entries for our Life Sciences Investment Tracker , identifying four more research programs and two more drugs...

STAT reporter Ed Silverman recently interviewed Incubate's execute director John Stanford for an article  on the EPIC Act's...

August was a momentous month for the life sciences ecosystem, and September looks to be just as significant. In this blog post, we want...

This bipartisan legislation would eliminate the small-molecule penalty by aligning the price-setting timeline for small and large...